Argenx: scaling a blockbuster immunology drug
The guest argued Argenx (RGX) is a quality growth investment, with its blockbuster drug VYVGART seeing explosive revenue growth and a clear pathway to sustained profitability following FDA approvals for new formulations and indications.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.